Pacific Biosciences Balances Consumable Strength With Headwinds

Pacific Biosciences ((PACB)) has held its Q1 earnings call. Read on for the main highlights of the call.

Pacific Biosciences’ latest earnings call struck a cautiously balanced tone, with executives highlighting solid momentum in consumables, clinical adoption and new technology launches, even as flat revenue, weaker instrument sales and margin pressure weighed on near‑term results. Management stressed that recent strategic moves and cost discipline are improving the company’s long‑term positioning despite a tougher operating backdrop.

Record Consumable Growth Underpins Revenue Mix

Consumables remained the bright spot, delivering a third straight record quarter with Q1 revenue of $21.8 million, up 9% year over year from $20.1 million. This shift is reshaping PacBio’s model toward a more recurring revenue base, partially offsetting softness in big‑ticket instrument sales and anchoring investor confidence in underlying demand.

Clinical Adoption Drives Surge in Consumable Shipments

Shipments to clinically focused accounts more than doubled versus last year, with clinical volumes now in the mid‑teens as a percentage of total consumable shipments. That mix roughly doubled from the prior year, signaling that hospitals and diagnostic labs are moving beyond pilots and beginning to embed PacBio’s long‑read technology into routine workflows.

Revio Pull‑Through Holds Steady as Installed Base Grows

Revio systems continued to perform within expectations, with annualized consumable pull‑through per system of about $229,000, squarely in the company’s $225,000 to $250,000 target range. Shipments rose to 15 units in Q1, up from 12 a year ago, bringing cumulative Revio placements to 346 systems and providing a larger installed base to drive future consumable growth.

Vega Adoption Expands Customer Footprint

PacBio shipped 27 Vega systems in the quarter, essentially flat with the 28 units shipped a year earlier, but more than 85% of placements went to new customers. That skew toward first‑time buyers broadens the company’s HiFi sequencing footprint and sets up incremental consumable demand as those sites ramp up production.

EMEA Emerges as a Growth Engine

Europe, the Middle East and Africa posted standout performance, with regional revenue rising 17% year over year to $10.8 million. Management attributed the gain to strong consumables demand and the progression of clinical accounts from validation phases into full‑scale production, underscoring EMEA’s status as a key growth geography.

Portfolio Streamlining Enhances Focus and Liquidity

The company executed strategic portfolio actions by selling high‑throughput short‑read assets to Illumina, generating approximately $48.1 million in net cash proceeds. Alongside resolution of related litigation, these moves sharpen PacBio’s focus on long‑read sequencing and provide incremental capital to support core technology investments.

Basecamp Collaboration Showcases AI‑Scale Ambitions

PacBio announced a major collaboration with Basecamp Research to deeply sequence roughly 100,000 metagenomic samples in the Trillion Gene Atlas project, its largest HiFi effort to date. Management framed the deal as a showcase for the platform’s suitability in training large‑scale AI and biology models, potentially opening new demand vectors in computational genomics.

SPRQ‑Nx Launch Poised to Boost Yields and Economics

Beta testing of the SPRQ‑Nx chemistry delivered double‑digit yield improvements and enabled three uses per SMRT Cell, materially improving throughput economics for customers. A full commercial launch is planned later this month, with rollout to Vega later in the summer, and management expects the upgrade to drive stronger consumable utilization and improve system productivity.

Cost Controls Drive Operating Expense Declines

Non‑GAAP operating expenses fell 19% year over year to $49.9 million, down from $61.7 million in the prior‑year quarter, as the company tightened spending across the organization. Noncash share‑based compensation also dropped sharply to $3.8 million from $8.0 million, reflecting a leaner cost structure and a focus on preserving cash.

Non‑GAAP Loss Narrows as Efficiency Improves

The company’s non‑GAAP net loss improved to $35.9 million, or $0.12 per share, versus $44.4 million, or $0.15 per share, a year earlier. While still firmly in loss‑making territory, the progress suggests that cost reductions and higher‑margin consumable growth are beginning to narrow the gap toward eventual profitability.

Flat Revenue and Trimmed Outlook Temper Enthusiasm

Total revenue held flat at $37.2 million in Q1, unchanged from the prior year, reflecting a mixed demand environment across products and regions. In response, management reduced the high end of its 2026 revenue guidance by $5 million, now calling for a range of $165 million to $175 million and signaling a more cautious stance on near‑term growth.

Instrument Sales Slide on Pricing and Demand Pressure

Instrument revenue declined 12% year over year to $9.7 million, down from $11.0 million, as the company faced lower Revio average selling prices and promotional pricing on Vega. Demand was also constrained in certain regions, underscoring the sensitivity of capital equipment purchases to funding conditions and macro uncertainty.

Gross Margins Squeezed by Compute and Promotions

Non‑GAAP gross profit slipped to $13.8 million with a 37% margin, compared with $15.0 million and 40% a year earlier, as rising memory and compute costs weighed on profitability. A promotional Vega program compressed ASPs and one‑time inventory and warranty adjustments further pressured margins, limiting the benefit from higher consumable mix.

Compute Costs Limit Near‑Term Margin Upside

Looking ahead, management warned that ongoing memory and compute cost inflation will constrain the pace of margin expansion, even as scale improves. As a result, the company now expects 2026 gross‑margin improvement to land toward the lower end of its previously guided 100 to 400 basis‑point range, reinforcing a more conservative margin trajectory.

Asia Pacific Weakness Reflects China and Funding Headwinds

Asia Pacific revenue fell 16% year over year to $9.7 million, hurt by delayed purchases from key customers in China awaiting SPRQ‑Nx availability. Weaker academic funding across the region compounded the slowdown, highlighting the impact of external funding cycles on PacBio’s capital equipment pipeline.

Service Revenue Softness Adds to Top‑Line Pressure

Service and other revenue slipped about 7% year over year to $5.6 million from $6.0 million, adding another drag to the flat overall revenue line. The decline underscores that while consumables are growing, ancillary revenue streams are not yet providing a consistent offset to variability in hardware demand.

Geopolitical Disruptions Dent Middle East Execution

The company noted that some products could not be delivered into parts of the Middle East due to regional conflict, directly impacting instrument revenue in the quarter. These disruptions highlight the operational risks inherent in global deployments and add another layer of unpredictability to quarterly results.

Vega Pricing Volatility Highlights Funding Sensitivity

A temporary Vega promotion in Q1 depressed ASPs and made margins and unit revenue particularly volatile, though management expects pricing to normalize in Q2. Even so, executives emphasized ongoing demand sensitivity in the Americas, especially among academic and government customers facing tight budgets, which may continue to affect capital sales.

Cash Burn Persists Despite Asset Sale Proceeds

Unrestricted cash, cash equivalents and investments ended the quarter at about $276 million, only slightly below the $280 million level at year‑end despite the $48.1 million inflow from the Illumina asset sale. The near‑flat cash balance underscores that operating and investment needs still consume substantial resources, even as the company trims expenses.

Guidance Points to Consumables‑Led Growth Amid Margin Constraints

PacBio now forecasts 2026 revenue of $165 million to $175 million, with consumables expected to be the primary growth driver while assuming no major rebound in academic or government funding. Non‑GAAP operating expenses are guided down to $220 million to $225 million, and gross margins are expected to improve starting in Q2 but only toward the low end of the prior 100 to 400 basis‑point range, as higher compute costs and cautious capital spending temper upside.

PacBio’s earnings call painted a story of a company leaning into consumables, clinical adoption and technology upgrades while managing through cyclical and cost‑related headwinds. For investors, the message is that near‑term growth and margin expansion will be slower than once hoped, but structural improvements, strategic collaborations and a growing installed base could lay the groundwork for more durable gains when funding and macro conditions improve.